Hemoglobinopathies Market Size Grows at a CAGR of 8.75%

Introduction

Straits Research released its highly anticipated report, “Global Hemoglobinopathies Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 9.67 billion in 2025 and is projected to expand to USD 20.50 billion by 2034, registering a compound annual growth rate (CAGR) of 8.75%.

Market Dynamics

The growth of the global hemoglobinopathies market is strongly driven by the rising prevalence of sickle cell disease and β-thalassemia across the globe. The increasing number of individuals affected by these genetic blood disorders is fueling the demand for effective treatment options. According to the Centers for Disease Control and Prevention (CDC), around 100,000 people in the U.S. live with sickle cell disease, and globally, the number of affected newborns is expected to grow due to higher birth rates in regions with high disease prevalence, such as Sub-Saharan Africa and South Asia.

Further, the growing adoption of advanced gene and cell therapies, which aim to correct the underlying genetic mutations, are gaining traction as regulatory approvals expand and specialized treatment centers become more widespread. As a result, more patients are gaining access to potentially curative therapies, strengthening market growth prospects. Moreover, increasing government initiatives and awareness programs promoting early diagnosis and treatment of hemoglobin disorders are contributing to the overall expansion of the market. The national screening programs and newborn testing initiatives in various countries are improving disease management outcomes and supporting early therapeutic interventions.

However, the market faces restraints such as the high treatment costs associated with gene and cell therapies, which limit accessibility, particularly in low and middle-income countries. Despite these challenges, ongoing research collaborations, the entry of new biotech firms, and the development of cost-effective gene-editing platforms are expected to present new scope for market growth, making it a promising segment within the rare disease therapeutics landscape.

Market Highlights

• Type: The sickle cell disease segment dominated the market in 2025 with a revenue share of 58.37%.
• Treatment Type: The stem cell transplant segment is estimated to grow at the fastest pace, with a CAGR of 9.76%.
• End User: The hospitals segment dominated the market with a revenue share of 43.39% in 2025.
• Regional Insights: North America dominated the global market, accounting for 38.77% share in 2025. This growth is attributed to the expansion of government-supported screening and awareness programs.

Competitive Players

1. Sangamo Therapeutics, Inc.
2. Global Blood Therapeutics, Inc.
3. bluebird bio, Inc.
4. Emmaus Life Sciences Inc.
5. Pfizer, Inc.
6. Novartis AG
7. Prolong Pharmaceuticals, LLC
8. Bioverativ Inc.
9. Gamida Cell
10. Celgene Corporation
11. Alnylam Pharmaceuticals, Inc.
12. Merck & Co. Inc.
13. Biogen Inc.
14. CRISPR Therapeutics
15. Agios Pharmaceuticals, Inc.
16. Beam Therapeutics
17. Alexion Pharmaceuticals, Inc.
18. Fulcrum Therapeutics
19. CSL
20. Others

Recent Developments

Segmentation

1. By Type (2026-2034)
   1. Thalassemia
   2. Sickle Cell Disease
   3. Hemoglobin C disease
   4. Hemoglobin E disease
   5. Others
2. By Treatment Type (2026-2034)
   1. Blood Transfusion
   2. Gene Therapy
   3. Stem Cell Transplant
   4. Pharmacotherapy
   5. Others
3. By End User (2026-2034)
   1. Hospitals
   2. Specialty Clinics
   3. Ambulatory Surgical Centers
   4. Others